(0.00%) 5 213.50 points
(0.01%) 39 031 points
(-0.01%) 18 197 points
(-1.59%) $77.13
(-0.05%) $2.21
(-0.37%) $2 315.50
(-0.70%) $27.35
(-1.11%) $977.40
(0.10%) $0.930
(0.42%) $10.95
(0.24%) $0.801
(0.24%) $91.66
Quarter results tomorrow
(bmo 2024-05-09)
Expected move: +/- 13.76%
1.19% $ 6.79
@ $9.20
Wydano: 15 kov. 2024 @ 21:39
Zwrot: -26.20%
Poprzedni sygnał: kov. 15 - 15:44
Poprzedni sygnał:
Zwrot: 0.77 %
Live Chart Being Loaded With Signals
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases...
Stats | |
---|---|
Dzisiejszy wolumen | 869 208 |
Średni wolumen | 2.26M |
Kapitalizacja rynkowa | 467.19M |
EPS | $0 ( 2024-05-02 ) |
Następna data zysków | ( $-0.410 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.54 |
ATR14 | $0.0110 (0.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-14 | Mossler Mark | Buy | 27 430 | Stock Option (Right to Buy) |
2024-02-14 | Mossler Mark | Buy | 18 290 | Common Stock |
2024-04-01 | Anderson Kenneth Carl | Buy | 1 389 | Common Stock |
2024-04-01 | Dubin Glenn | Buy | 1 358 | Common Stock |
2024-04-01 | Grogan Donna Roy | Buy | 1 697 | Common Stock |
INSIDER POWER |
---|
59.65 |
Last 98 transactions |
Buy: 4 435 645 | Sell: 1 001 966 |
Wolumen Korelacja
C4 Therapeutics, Inc. Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
QRTEA | 0.96 |
PTRA | 0.959 |
EIGR | 0.957 |
STIM | 0.957 |
ASPU | 0.955 |
SSP | 0.955 |
MDRX | 0.954 |
AKTX | 0.954 |
PRCH | 0.954 |
PSTX | 0.952 |
10 Najbardziej negatywne korelacje | |
---|---|
STAY | -0.951 |
CCRC | -0.95 |
SGEN | -0.947 |
PAE | -0.944 |
EBSB | -0.94 |
PTOC | -0.931 |
DSPG | -0.93 |
PPYAU | -0.929 |
RAM | -0.92 |
LMNR | -0.918 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
C4 Therapeutics, Inc. Korelacja - Waluta/Towar
C4 Therapeutics, Inc. Finanse
Annual | 2023 |
Przychody: | $20.76M |
Zysk brutto: | $13.02M (62.72 %) |
EPS: | $-2.67 |
FY | 2023 |
Przychody: | $20.76M |
Zysk brutto: | $13.02M (62.72 %) |
EPS: | $-2.67 |
FY | 2022 |
Przychody: | $31.10M |
Zysk brutto: | $23.52M (75.65 %) |
EPS: | $-2.59 |
FY | 2021 |
Przychody: | $45.79M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-1.730 |
Financial Reports:
No articles found.
C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej